Compare United States Brent Oil Fund LP (BNO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Brent Oil Fund LP vs Recursion Pharmaceuticals Inc — how do they compare? United States Brent Oil Fund LP trades at $50.75, while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: United States Brent Oil Fund LP is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| BNO | RXRX | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $60.13 | $6.79 |
52-Week Low | $27.20 | $2.84 |
Market Cap | — | $1.81B |
Enterprise Value | — | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNO is trading at $50.505, up 0.79% with a bullish technical outlook supported by moving averages. The oil market faces significant supply disruptions from Middle East tensions, particularly the Strait of Hormuz closure, creating volatility. Recent OPEC demand forecast cuts contrast with supply constraints, creating a complex fundamental backdrop for oil-related securities.
The stock presents opportunity from ongoing supply constraints but faces headwinds from demand destruction and inventory builds. Key risks include geopolitical resolution and demand volatility. Technical momentum remains positive near-term, but fundamental uncertainties require careful monitoring of oil market developments.
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About United States Brent Oil Fund LP
BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.
Read more on BNO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
